Replies to post #93995 on $heff's $tation of $tocks & $olid DD

[momentum74]

DNAI 5.50 news.Phase 2 on June 6th at ASCO

Stock should have a strong run into June 6th was 33.75 at its peak imo.

News link
http://finance.yahoo.com/news/pronai-report-wolverine-phase-2-220000746.html

- ProNAi to hold Analyst & Investor Event at 7:00am CT on June 6th -
- ProNAi to Present at Jefferies 2016 Healthcare Conference in New York on June 9th –

VANCOUVER, May 18, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (DNAI), a clinical-stage oncology company advancing novel targeted therapeutics for patients with cancer, today announced it will present interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) on June 6th at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).

Analyst & Investor Event
ProNAi will host an Analyst and Investor Event on Monday, June 6, 2016 from 7:00 - 8:00am CT where the company will present an update on the PNT2258 development program, including interim results from the Wolverine Phase 2 trial. Presenters will include: Dr. Nick Glover, President and Chief Executive Officer, Dr. Barbara Klencke, Chief Development Officer, and Dr. Angie You, Chief Business & Strategy Officer and Head of Commercial. The event will take place in the Hyde Park A/CC11A event room at the Hyatt Regency McCormick Place located at 2233 S. Dr. Martin Luther King Jr. Dr., Chicago, Illinois. This event will be webcast live and will be accessible through the company's website at www.pronai.com. An archived replay of the webcast will also be available.

ASCO 2016 Poster Presentation
Title: A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): An initial report from the Wolverine study
Trials in Progress Abstract: #TPS7577
Poster: #130b
Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: Monday, June 6, 2016, 8:00 – 11:30am CT
Location: McCormick Place, Event room: Hall A, 2301 S King Dr, Chicago, Illinois
Track: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Jason R. Westin, MD, MS, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center
The poster will be available on June 6, 2016 on the company's website at www.pronai.com

Jefferies 2016 Healthcare Conference in New York, NY
Dr. Nick Glover, President and Chief Executive Officer of ProNAi, will present an overview of the company at the Jefferies 2016 Healthcare Conference, being held at the Grand Hyatt Hotel in New York, NY. The presentation is scheduled for 2:30pm (Eastern Time) on Thursday, June 9th. A live webcast of the presentation will be accessible through the ProNAi website at www.pronai.com. An archived replay of the presentation will also be available.

About ProNAi Therapeutics
ProNAi Therapeutics is a clinical-stage oncology company advancing novel targeted therapeutics for patients with cancer. ProNAi's lead product candidate, PNT2258, is designed to target cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is evaluating PNT2258 in two Phase 2 trials: "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL); and "Brighton", a Phase 2 trial evaluating PNT2258 for the treatment of Richter's transformation. For more information, please visit www.pronai.com.